ERBB2 and gastric cancer: In disagreement with Yasui et al., who concluded that it was impossible to distinguish any variations in FGFR2 or HER2 status based on primary cancer’s location or histological subtype, there were notable variances between the various histological kinds of gastric cancer; however, FGFR2 and HER2 status did not vary according to the main cancer location, due to the small number of FGFR2-positive colorectal cancer patients without full validation of their results [57].